All three commercially available TNF antagonists, adalimumab (Humira; Abbott Laboratories, Abbott Park, Illinois, USA), etanercept (Enbrel; Immunex, Thousand Oaks, California, USA) and infliximab (Remicade; Centocor, Inc, Malvern, Pennsylvania, USA), are indicated for RA, PsA, AS and psoriasis.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 Adalimumab and infliximab are also indicated for CD; adalimumab and etanercept are indicated for JIA.16, 17, 18, 19, 20, 21. This evidence concerns the gene TNF and psoriasis.